Recent developments include completion of dosing in the Phase 1b trial of SER-252 for Parkinson's disease, board appointments, financing activities, and regulatory compliance progress.

• Serina appointed Simon to its board and concluded dosing in the Phase 1b trial for SER-252 targeting Parkinson's disease [N1].
• The NYSE American accepted Serina's continued listing compliance plan in April 2026, allowing the company to maintain its listing subject to ongoing review [N3].
• Registration opened for Tribe Public’s CEO presentation and Q&A webinar event in February 2026 [N4].
• Serina received a NYSE deficiency notification regarding shareholders' equity in January 2026 [N5].
• Serina presented next-generation approaches for Parkinson’s care at the FORCE Family Office Webinar in June 2025 [N6].
• Serina congratulated Juvenescence on securing $150 million Series B financing and a strategic alliance with M42 in June 2025 [N7].
• Dr. Stephen Brannan was appointed to Serina's board to enhance CNS therapeutic development in May 2025 [N8].

Serina Therapeutics has advanced its lead candidate SER-252 into registrational Phase 1b clinical trials with dosing completed, supported by FDA clearance. The company has secured financing to support ongoing development and strengthened its leadership and governance. Strong liquidity ratios as of mid-2026 provide runway for near-term operations. Strategic partnerships and presentations at industry events demonstrate active engagement in advancing its therapeutic approach for Parkinson's disease. The company's compliance with NYSE American listing standards under an accepted plan supports continued market presence.

Serina Therapeutics operates with substantial doubt about its ability to continue as a going concern due to ongoing operating losses and negative cash flows. The company requires additional financing to advance SER-252 and other programs, with risks that such financing may not be available on acceptable terms. Ownership concentration by a few investors may limit broader shareholder influence and could lead to conflicts of interest. Clinical development risks remain significant given the early-stage status of SER-252. Failure to maintain NYSE American listing compliance could adversely affect liquidity and capital raising ability.

Serina Therapeutics' moat is primarily based on its proprietary therapeutic candidate SER-252 targeting advanced Parkinson's disease, a significant unmet medical need. The company's early-stage clinical development progress, including FDA clearance and Phase 1b trial dosing completion, establishes initial clinical validation. Strategic partnerships and a strengthened leadership team contribute to its development capabilities. However, as a clinical-stage biopharmaceutical company, Serina faces typical industry risks including clinical trial uncertainties, regulatory hurdles, and capital requirements. The concentration of ownership and governance influence by key investors may impact strategic decisions and shareholder alignment.

• Ownership Concentration and Governance Risks: Dr. Gregory H. Bailey and Juvenescence collectively hold a significant ownership stake (approximately 58%) and governance influence, which may limit other stockholders' ability to influence corporate matters and could lead to conflicts of interest or decisions not aligned with all shareholders [S2].
• Going Concern and Financing Risks: The company has a history of operating losses and negative cash flows, with substantial doubt about its ability to continue as a going concern. Additional financing is required to fund operations and clinical development; failure to secure capital could result in delays or termination of programs [S2].
• Clinical Development Risks: SER-252 is in early-stage clinical development, and clinical trials are lengthy, expensive, and uncertain. Early-stage results may not predict later outcomes or regulatory approvals [S2].
• Listing Compliance Risks: Serina operates under an accepted NYSE American continued listing compliance plan following a deficiency notice related to shareholders' equity. Failure to maintain compliance could lead to delisting, reducing stock liquidity and capital raising ability [N3][N5][S2].
• Dilution Risks: Outstanding warrants and equity-linked securities, including those issued in recent financings, could result in substantial dilution to existing shareholders [S2].

• Serina Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing SER-252, a therapeutic candidate for advanced Parkinson's disease [N1][S1][S2].
• The company is incorporated in Delaware and headquartered in Huntsville, Alabama [S1].
• SER-252 is in early-stage clinical development, with a Phase 1b registrational clinical trial initiated in February 2026 and dosing concluded in July 2026 [N1][S2].
• The FDA cleared the investigational new drug application for SER-252 in January 2026 [S2].
• Serina completed a $21.2 million private investment in public equity (PIPE) financing in March 2026, improving liquidity [N7][S2].
• As of June 30, 2026, Serina had cash and cash equivalents of approximately $23.0 million and total stockholders' equity of approximately $18.7 million [S2].
• The company reported a net loss of $6.356 million and basic and diluted EPS of -$0.55 for the quarter ended June 30, 2026 [S2].
• Liquidity ratios as of June 30, 2026, include a current ratio of 6.65 and a cash ratio of 6.12, indicating strong short-term liquidity [S2].
• The company operates under an accepted NYSE American continued listing compliance plan after receiving a deficiency notice related to shareholders' equity in January 2026 [N3][N5][S2].
• Significant ownership concentration exists: Dr. Gregory H. Bailey, a board member and Co-Chairman, beneficially owns approximately 41% of common stock, and Juvenescence owns approximately 17%, with aligned interests [S2].
• The March 2026 PIPE involved Dr. Bailey acquiring significant ownership and governance rights, including appointment as Co-Chairman and influence over board composition [S2].
• The company has a history of operating losses and negative cash flows, with substantial doubt about its ability to continue as a going concern noted by auditors [S2].
• The company requires additional financing to advance SER-252 and other programs; inability to raise capital could lead to delays or termination of research and development programs [S2].
• Outstanding warrants and equity-linked securities could cause dilution to existing shareholders [S2].
• Serina has strengthened leadership and financial position through recent appointments to the board, including Dr. Stephen Brannan and Simon, and strategic partnerships such as with Gannet BioChem [N1][N8].
• The company has presented novel data on non-immunogenic lipid nanoparticles and next-generation approaches for Parkinson's care at industry events [N6].